NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report

Abstract Background NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window for reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data of drug safety and combination with other medications especially anticoagulants ar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Misya’il Abdul Rashid, Mohamad Syafeeq Faeez Md Noh, Abdul Hanif Khan Yusof Khan, Wei Chao Loh, Janudin Baharin, Azliza Ibrahim, Liyana Najwa Inche Mat, Wan Aliaa Wan Sulaiman, Fan Kee Hoo, Fazah Akhtar Hanapiah, Hamidon Basri
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	Stroke Chinese traditional medication Hepatotoxicity NeuroAid II Elderly Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/8e2912eb01e540368284ee5b4ff77d01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8e2912eb01e540368284ee5b4ff77d01
record_format	dspace
spelling	oai:doaj.org-article:8e2912eb01e540368284ee5b4ff77d012021-11-08T10:44:30ZNeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report10.1186/s41983-021-00397-y1687-8329https://doaj.org/article/8e2912eb01e540368284ee5b4ff77d012021-11-01T00:00:00Zhttps://doi.org/10.1186/s41983-021-00397-yhttps://doaj.org/toc/1687-8329Abstract Background NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window for reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data of drug safety and combination with other medications especially anticoagulants are heterogenous. We report a possible case of hepatotoxicity induced by NeuroAid II in combination with anticoagulants. Case presentation We report an elderly patient who developed symptoms of cardioembolic stroke presented outside of time window for reperfusion therapy. He was started on a regiment of statins, anticoagulation, beta blockers and NeuroAid II. One month later he presented with deranged liver enzymes. Cessation of NeuroAid II resulted in rapid improvement of transaminitis within days. Conclusions We wish to highlight the potential harmful effect of administering NeuroAid II with an anticoagulant and the importance of routine follow-up and blood monitoring in the elderly patients with stroke.Anna Misya’il Abdul RashidMohamad Syafeeq Faeez Md NohAbdul Hanif Khan Yusof KhanWei Chao LohJanudin BaharinAzliza IbrahimLiyana Najwa Inche MatWan Aliaa Wan SulaimanFan Kee HooFazah Akhtar HanapiahHamidon BasriSpringerOpenarticleStrokeChinese traditional medicationHepatotoxicityNeuroAid IIElderlyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery, Vol 57, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Stroke Chinese traditional medication Hepatotoxicity NeuroAid II Elderly Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Stroke Chinese traditional medication Hepatotoxicity NeuroAid II Elderly Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Anna Misya’il Abdul Rashid Mohamad Syafeeq Faeez Md Noh Abdul Hanif Khan Yusof Khan Wei Chao Loh Janudin Baharin Azliza Ibrahim Liyana Najwa Inche Mat Wan Aliaa Wan Sulaiman Fan Kee Hoo Fazah Akhtar Hanapiah Hamidon Basri NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
description	Abstract Background NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window for reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data of drug safety and combination with other medications especially anticoagulants are heterogenous. We report a possible case of hepatotoxicity induced by NeuroAid II in combination with anticoagulants. Case presentation We report an elderly patient who developed symptoms of cardioembolic stroke presented outside of time window for reperfusion therapy. He was started on a regiment of statins, anticoagulation, beta blockers and NeuroAid II. One month later he presented with deranged liver enzymes. Cessation of NeuroAid II resulted in rapid improvement of transaminitis within days. Conclusions We wish to highlight the potential harmful effect of administering NeuroAid II with an anticoagulant and the importance of routine follow-up and blood monitoring in the elderly patients with stroke.
format	article
author	Anna Misya’il Abdul Rashid Mohamad Syafeeq Faeez Md Noh Abdul Hanif Khan Yusof Khan Wei Chao Loh Janudin Baharin Azliza Ibrahim Liyana Najwa Inche Mat Wan Aliaa Wan Sulaiman Fan Kee Hoo Fazah Akhtar Hanapiah Hamidon Basri
author_facet	Anna Misya’il Abdul Rashid Mohamad Syafeeq Faeez Md Noh Abdul Hanif Khan Yusof Khan Wei Chao Loh Janudin Baharin Azliza Ibrahim Liyana Najwa Inche Mat Wan Aliaa Wan Sulaiman Fan Kee Hoo Fazah Akhtar Hanapiah Hamidon Basri
author_sort	Anna Misya’il Abdul Rashid
title	NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
title_short	NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
title_full	NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
title_fullStr	NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
title_full_unstemmed	NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
title_sort	neuroaid ii (mlc901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/8e2912eb01e540368284ee5b4ff77d01
work_keys_str_mv	AT annamisyailabdulrashid neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT mohamadsyafeeqfaeezmdnoh neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT abdulhanifkhanyusofkhan neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT weichaoloh neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT janudinbaharin neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT azlizaibrahim neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT liyananajwainchemat neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT wanaliaawansulaiman neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT fankeehoo neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT fazahakhtarhanapiah neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport AT hamidonbasri neuroaidiimlc901andpolypharmacyinstrokeandtheriskofhepatotoxicityacasereport
_version_	1718442639544549376

NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report

Ejemplares similares